Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A.
about
An update on antibody-based immunotherapies for Clostridium difficile infectionBiochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin AThe roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice.The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.Human monoclonal single-chain antibodies specific to dengue virus envelope protein.Future novel therapeutic agents for Clostridium difficile infection.Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet modelColonization Resistance of the Gut Microbiota against Clostridium difficile.Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.Pseudomembranous colitis due to Clostridium difficile as a cause of perineal necrotising fasciitis.Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?Clostridium difficile associated infection, diarrhea and colitisA Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.Clostridium difficile infection in the twenty-first century.Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013The enterotoxicity of Clostridium difficile toxins.Antibodies for treatment of Clostridium difficile infection.Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?Emerging monoclonal antibodies against Clostridium difficile infection.Bezlotoxumab for the prevention of Clostridium difficile recurrence.A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection.Immunisation of mares with binding domains of toxins A and B of Clostridium difficile elicits serum and colostral antibodies that block toxin binding.Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection.
P2860
Q26740788-DCD405D8-415E-4649-9D90-61D65B4AD1F5Q28547242-7D816E23-3A08-4C13-B410-1EE39921F134Q33728318-31F1C82F-C413-46EA-980C-83AD15583097Q33896435-BC56CF41-2371-4E67-953D-4B26BEE6483FQ34623572-B693964C-219F-4070-900D-242A4FD2FBECQ35050826-EE39B289-854B-4B22-916B-B6B83D99EF57Q35175136-AEF5DA4C-7EEE-4AD5-AE6B-02401DB0BBFDQ35368495-24B6B7F9-ED4B-4CC7-9DA8-E970FAEB7CBFQ35973168-25FFDA57-AC34-4ABD-B2AA-F0DAE435D355Q36495548-B43287E2-FFE5-49A3-85A8-1C28AB9EE8E0Q36705215-C9AB6DFE-77BA-447B-A0EB-0A6A8BD0EE62Q37064733-7E737E4E-B978-4CE6-A1FC-265E362FF02EQ37160538-5F05FAFA-9FA1-4F6A-A47A-64DDF4205D26Q37239550-CBB17CD3-CEA6-4A2A-8381-BA0AE718104CQ37258250-F4433C01-07B7-4856-8EBD-0EE4AEAD2789Q37289567-C28A5A92-CCE0-4258-A458-55C15F52D424Q37496388-1D40C3DB-C645-4EDC-B986-AC382781CAA1Q37954308-DDB3AC8B-E1F6-4DC9-84C0-8BDB698167C1Q38208794-3D6CEC8C-3D8C-4A98-9E60-B40DC11318DCQ38686710-59F6C204-C82C-4B59-9777-7D127220E843Q39168914-F579B970-F35D-4406-8FB9-9A0F1B610CDBQ40095035-47B91711-2F36-492D-97B2-78EEF5435A94Q46242399-980A6720-B49C-425D-B3DD-89903C6524AFQ46523280-543DB739-BB89-4BFF-8355-D6CD2D1C9887Q49201152-83683DAB-AD3B-4E9F-81FB-1DE5950FDFDDQ54321930-53A37A42-826E-46EF-9668-C87685D794AFQ55516782-8D35601F-1E90-4CE3-A2F1-41F3648C43C6
P2860
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Open-label, dose escalation ph ...... Clostridium difficile toxin A.
@en
Open-label, dose escalation ph ...... Clostridium difficile toxin A.
@nl
type
label
Open-label, dose escalation ph ...... Clostridium difficile toxin A.
@en
Open-label, dose escalation ph ...... Clostridium difficile toxin A.
@nl
prefLabel
Open-label, dose escalation ph ...... Clostridium difficile toxin A.
@en
Open-label, dose escalation ph ...... Clostridium difficile toxin A.
@nl
P2093
P2860
P1433
P1476
Open-label, dose escalation ph ...... Clostridium difficile toxin A.
@en
P2093
Anthony Lembo
Ciaran P Kelly
Claribel P Taylor
Deborah Molrine
Israel Lowy
Lisa Davidson
Patricia L Hibberd
Richard J Farrell
Sanjeev Tummala
P2860
P304
P356
10.1016/J.VACCINE.2008.04.042
P407
P577
2008-05-07T00:00:00Z